January 13, 2020
MBF Therapeutics, Smithfield Foods ink agreement to develop new swine vaccines
MBF Therapeutics Inc., a company that develops DNA-based immunotherapeutic vaccines for the animal health market, has signed an agreement with leading meat processor Smithfield Foods Inc. to collaborate in developing new swine vaccines.
In creating more effective swine vaccines, the Philadelphia, USA-based company said it will use its gene-based, T-cell directed vaccine platform and novel calcium phosphate delivery system.
"By eliciting responses in both T-cells and B-cells, these new and more effective swine vaccines will have the potential to reduce the use of antibiotics, chronic disease, and endemic viral reservoirs in pork production", it said.
MBF Therapeutics CEO Thomas Tillett said the first phase of the collaborative project is the development of a more effective vaccine for porcine reproductive respiratory syndrome (PRRS) using MBFT's calcium phosphate nanoparticle delivery. PRRS occurs worldwide in nearly all swine-producing countries and is currently the most economically significant disease that threatens US swine production.
It is believed that several inactivated, attenuated vaccines for PRRS on the market underperform.
The second phase involves addressing the long-term need for better protective immunity to economically significant porcine viral infections through the development of next-generation DN vaccines. "Whether it is taking PRRS protection to the next level, addressing the need for a cross-protective swine influenza vaccine, or applying a gene-based immunomodulator approach to solving the urgent need for a safe, cross protective and durable African swine fever vaccine, MBFT technology offers an innovative approach to vaccine design that is well suited for use in livestock", Tillett said.
"We are pleased to have the opportunity to work with Smithfield on designing and developing new vaccines for infectious swine diseases", said Tillett. "This collaboration will enable MBF Therapeutics to move research forward with our innovative gene-based, T-cell directed vaccine platform technology, which has great potential for transforming infectious disease protection".